Advertisement

Special Types of Invasive Breast Carcinoma

  • Javier A. Arias-StellaIII
  • Isabel Alvarado-Cabrero
  • Fresia Pareja
Chapter

Abstract

Breast carcinoma is a vastly heterogeneous disease encompassing a wide array of entities with different morphology, biology, clinical behavior, and prognosis. Special types of breast carcinoma include tumors with morphologies that deviate from invasive carcinoma of no special type (NST). As a group, special types comprise up to 25% of all breast cancers, and encompass entities ranging from low to high-grade, and with different hormone receptor and HER2 status. The recognition of the different special types of breast cancer is of paramount importance, as their proper classification is relevant not only for taxonomic purposes, but has also for therapeutic implications.

Keywords

Breast cancer Special types Morphology Classification Taxonomy 

References

  1. 1.
    McCart Reed AE, Kutasovic JR, Lakhani SR, Simpson PT. Invasive lobular carcinoma of the breast: morphology, biomarkers and omics. Breast Cancer Res. 2015;17:12.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Li CI, Anderson BO, Daling JR, Moe RE. Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA. 2003;289(11):1421–4.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Chen Z, Yang J, Li S, Lv M, Shen Y, Wang B, et al. Invasive lobular carcinoma of the breast: a special histological type compared with invasive ductal carcinoma. PLoS One. 2017;12(9):e0182397.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Lewis TR, Casey J, Buerk CA, Cammack KV. Incidence of lobular carcinoma in bilateral breast cancer. Am J Surg. 1982;144(6):635–8.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Kim SH, Cha ES, Park CS, Kang BJ, Whang IY, Lee AW, et al. Imaging features of invasive lobular carcinoma: comparison with invasive ductal carcinoma. Jpn J Radiol. 2011;29(7):475–82.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Le Gal M, Ollivier L, Asselain B, Meunier M, Laurent M, Vielh P, et al. Mammographic features of 455 invasive lobular carcinomas. Radiology. 1992;185(3):705–8.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Porter AJ, Evans EB, Foxcroft LM, Simpson PT, Lakhani SR. Mammographic and ultrasound features of invasive lobular carcinoma of the breast. J Med Imaging Radiat Oncol. 2014;58(1):1–10.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Gruber IV, Rueckert M, Kagan KO, Staebler A, Siegmann KC, Hartkopf A, et al. Measurement of tumour size with mammography, sonography and magnetic resonance imaging as compared to histological tumour size in primary breast cancer. BMC Cancer. 2013;13:328.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Parvaiz MA, Yang P, Razia E, Mascarenhas M, Deacon C, Matey P, et al. Breast MRI in invasive lobular carcinoma: a useful investigation in surgical planning? Breast J. 2016;22(2):143–50.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Fechner RE. Histologic variants of infiltrating lobular carcinoma of the breast. Hum Pathol. 1975;6(3):373–8.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Shousha S, Backhous CM, Alaghband-Zadeh J, Burn I. Alveolar variant of invasive lobular carcinoma of the breast. A tumor rich in estrogen receptors. Am J Clin Pathol. 1986;85(1):1–5.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Esposito NN, Chivukula M, Dabbs DJ. The ductal phenotypic expression of the E-cadherin/catenin complex in tubulolobular carcinoma of the breast: an immunohistochemical and clinicopathologic study. Mod Pathol. 2007;20(1):130–8.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Butler D, Rosa M. Pleomorphic lobular carcinoma of the breast: a morphologically and clinically distinct variant of lobular carcinoma. Arch Pathol Lab Med. 2013;137(11):1688–92.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Menet E, Becette V, Briffod M. Cytologic diagnosis of lobular carcinoma of the breast: experience with 555 patients in the Rene Huguenin Cancer Center. Cancer. 2008;114(2):111–7.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Derksen PW, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell. 2006;10(5):437–49.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Moriya T, Kozuka Y, Kanomata N, Tse GM, Tan PH. The role of immunohistochemistry in the differential diagnosis of breast lesions. Pathology. 2009;41(1):68–76.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Da Silva L, Parry S, Reid L, Keith P, Waddell N, Kossai M, et al. Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol. 2008;32(5):773–83.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Sahin S, Karatas F, Erdem GU, Hacioglu B, Altundag K. Invasive pleomorphic lobular histology is an adverse prognostic factor on survival in patients with breast cancer. Am Surg. 2017;83(4):359–64.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell. 2015;163(2):506–19.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: how special are they? Mol Oncol. 2010;4(3):192–208.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Mamtani A, King TA. Lobular breast cancer: different disease, different algorithms? Surg Oncol Clin N Am. 2018;27(1):81–94.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Sakr RA, Poulet B, Kaufman GJ, Nos C, Clough KB. Clear margins for invasive lobular carcinoma: a surgical challenge. Eur J Surg Oncol. 2011;37(4):350–6.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Monhollen L, Morrison C, Ademuyiwa FO, Chandrasekhar R, Khoury T. Pleomorphic lobular carcinoma: a distinctive clinical and molecular breast cancer type. Histopathology. 2012;61(3):365–77.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Rakha EA, Lee AH, Evans AJ, Menon S, Assad NY, Hodi Z, et al. Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol. 2010;28(1):99–104.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Leibman AJ, Lewis M, Kruse B. Tubular carcinoma of the breast: mammographic appearance. AJR Am J Roentgenol. 1993;160(2):263–5.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Sheppard DG, Whitman GJ, Huynh PT, Sahin AA, Fornage BD, Stelling CB. Tubular carcinoma of the breast: mammographic and sonographic features. AJR Am J Roentgenol. 2000;174(1):253–7.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Rakha E, Pinder SE, Shin SJ, Tsuda H. Tubular carcioma and cribriform carcinoma. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, MJvd V, editors. WHO classification of tumours of the breast. Lyon: IARC; 2012.Google Scholar
  28. 28.
    Cangiarella J, Waisman J, Shapiro RL, Simsir A. Cytologic features of tubular adenocarcinoma of the breast by aspiration biopsy. Diagn Cytopathol. 2001;25(5):311–5.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Dieci MV, Orvieto E, Dominici M, Conte P, Guarneri V. Rare breast cancer subtypes: histological, molecular, and clinical peculiarities. Oncologist. 2014;19(8):805–13.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    de Moraes Schenka NG, Schenka AA, de Souza Queiroz L, de Almeida Matsura M, Alvarenga M, Vassallo J. p63 and CD10: reliable markers in discriminating benign sclerosing lesions from tubular carcinoma of the breast? Appl Immunohistochem Mol Morphol. 2006;14(1):71–7.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Spruill L. Benign mimickers of malignant breast lesions. Semin Diagn Pathol. 2016;33(1):2–12.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Albrektsen G, Heuch I, Thoresen SO. Histological type and grade of breast cancer tumors by parity, age at birth, and time since birth: a register-based study in Norway. BMC Cancer. 2010;10:226.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat. 2008;111(3):541–7.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Tan PH, Tse GM, Bay BH. Mucinous breast lesions: diagnostic challenges. J Clin Pathol. 2008;61(1):11–9.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Bitencourt AG, Graziano L, Osório CA, Guatelli CS, Souza JA, Mendonça MH, et al. MRI features of mucinous cancer of the breast: correlation with pathologic findings and other imaging methods. AJR Am J Roentgenol. 2016;206(2):238–46.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Lam WW, Chu WC, Tse GM, Ma TK. Sonographic appearance of mucinous carcinoma of the breast. AJR Am J Roentgenol. 2004;182(4):1069–74.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Linda A, Zuiani C, Girometti R, Londero V, Machin P, Brondani G, et al. Unusual malignant tumors of the breast: MRI features and pathologic correlation. Eur J Radiol. 2010;75(2):178–84.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Capella C, Eusebi V, Mann B, Azzopardi JG. Endocrine differentiation in mucoid carcinoma of the breast. Histopathology. 1980;4(6):613–30.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Lacroix-Triki M, Suarez PH, MacKay A, Lambros MB, Natrajan R, Savage K, et al. Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J Pathol. 2010;222(3):282–98.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Laucirica R, Bentz JS, Khalbuss WE, Clayton AC, Souers RJ, Moriarty AT. Performance characteristics of mucinous (colloid) carcinoma of the breast in fine-needle aspirates: observations from the College of American Pathologists Interlaboratory Comparison Program in Nongynecologic Cytopathology. Arch Pathol Lab Med. 2011;135(12):1533–8.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Tang SL, Yang JQ, Du ZG, Tan QW, Zhou YT, Zhang D, et al. Clinicopathologic study of invasive micropapillary carcinoma of the breast. Oncotarget. 2017;8(26):42455–65.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Edelweiss M, Corben AD, Liberman L, Kaplan J, Nehhozina T, Catalano JP, et al. Focal extravasated mucin in breast core needle biopsies: is surgical excision always necessary? Breast J. 2013;19(3):302–9.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Cao AY, He M, Liu ZB, Di GH, Wu J, Lu JS, et al. Outcome of pure mucinous breast carcinoma compared to infiltrating ductal carcinoma: a population-based study from China. Ann Surg Oncol. 2012;19(9):3019–27.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Ranade A, Batra R, Sandhu G, Chitale RA, Balderacchi J. Clinicopathological evaluation of 100 cases of mucinous carcinoma of breast with emphasis on axillary staging and special reference to a micropapillary pattern. J Clin Pathol. 2010;63(12):1043–7.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Paterakos M, Watkin WG, Edgerton SM, Moore DH 2nd, Thor AD. Invasive micropapillary carcinoma of the breast: a prognostic study. Hum Pathol. 1999;30(12):1459–63.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Alsharif S, Daghistani R, Kamberoğlu EA, Omeroglu A, Meterissian S, Mesurolle B. Mammographic, sonographic and MR imaging features of invasive micropapillary breast cancer. Eur J Radiol. 2014;83(8):1375–80.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Adrada B, Arribas E, Gilcrease M, Yang WT. Invasive micropapillary carcinoma of the breast: mammographic, sonographic, and MRI features. AJR Am J Roentgenol. 2009;193(1):W58–63.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Yang YL, Liu BB, Zhang X, Fu L. Invasive micropapillary carcinoma of the breast: an update. Arch Pathol Lab Med. 2016;140(8):799–805.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Nassar H. Carcinomas with micropapillary morphology: clinical significance and current concepts. Adv Anat Pathol. 2004;11(6):297–303.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Siriaunkgul S, Tavassoli FA. Invasive micropapillary carcinoma of the breast. Mod Pathol. 1993;6(6):660–2.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Kelten EC, Akbulut M, Duzcan SE. Diagnostic dilemma in cytologic features of micropapillary carcinoma of the breast: a report of 2 cases. Acta Cytol. 2009;53(4):463–6.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Vingiani A, Maisonneuve P, Dell'orto P, Farante G, Rotmensz N, Lissidini G, et al. The clinical relevance of micropapillary carcinoma of the breast: a case-control study. Histopathology. 2013;63(2):217–24.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Yang W, Wei B, Chen M, Bu H. Evaluation of immunohistochemistry HER2 results interpretation in invasive micropapillary carcinoma of the breast. Zhonghua Bing Li Xue Za Zhi. 2015;44(1):48–52.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Stewart RL, Caron JE, Gulbahce EH, Factor RE, Geiersbach KB, Downs-Kelly E. HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features. Mod Pathol. 2017;30(11):1561–6.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013.PubMedCrossRefGoogle Scholar
  56. 56.
    Nassar H, Pansare V, Zhang H, Che M, Sakr W, Ali-Fehmi R, et al. Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoprotein. Mod Pathol. 2004;17(9):1045–50.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Pettinato G, Manivel CJ, Panico L, Sparano L, Petrella G. Invasive micropapillary carcinoma of the breast: clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior. Am J Clin Pathol. 2004;121(6):857–66.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Lepe M, Kalife ET, Ou J, Quddus MR, Singh K. ‘Inside-out’ p120 immunostaining pattern in invasive micropapillary carcinoma of the breast; additional unequivocal evidence of reversed polarity. Histopathology. 2017;70(5):832–4.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Ueng SH, Mezzetti T, Tavassoli FA. Papillary neoplasms of the breast: a review. Arch Pathol Lab Med. 2009;133(6):893–907.PubMedPubMedCentralGoogle Scholar
  60. 60.
    Marchiò C, Iravani M, Natrajan R, Lambros MB, Savage K, Tamber N, et al. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol. 2008;215(4):398–410.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Natrajan R, Wilkerson PM, Marchiò C, Piscuoglio S, Ng CK, Wai P, et al. Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. J Pathol. 2014;232(5):553–65.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Lotan TL, Ye H, Melamed J, Wu XR, Shih IM, Epstein JI. Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma. Am J Surg Pathol. 2009;33(7):1037–41.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Guo X, Chen L, Lang R, Fan Y, Zhang X, Fu L. Invasive micropapillary carcinoma of the breast: association of pathologic features with lymph node metastasis. Am J Clin Pathol. 2006;126(5):740–6.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Chen HL, Ding A. Comparison of invasive micropapillary and triple negative invasive ductal carcinoma of the breast. Breast. 2015;24(6):723–31.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Chen AC, Paulino AC, Schwartz MR, Rodriguez AA, Bass BL, Chang JC, et al. Population-based comparison of prognostic factors in invasive micropapillary and invasive ductal carcinoma of the breast. Br J Cancer. 2014;111(3):619–22.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Liu F, Yang M, Li Z, Guo X, Lin Y, Lang R, et al. Invasive micropapillary mucinous carcinoma of the breast is associated with poor prognosis. Breast Cancer Res Treat. 2015;151(2):443–51.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Barbashina V, Corben AD, Akram M, Vallejo C, Tan LK. Mucinous micropapillary carcinoma of the breast: an aggressive counterpart to conventional pure mucinous tumors. Hum Pathol. 2013;44(8):1577–85.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Madur B, Shet T, Chinoy R. Cytologic findings in infiltrating micropapillary carcinoma and mucinous carcinomas with micropapillary pattern. Acta Cytol. 2007;51(1):25–32.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Jain S, Khurana N, Rao S, Garg A, Kaza R. Psammomatous colloid carcinoma of the breast with micropapillary pattern. Breast J. 2012;18(2):178–80.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Pedersen L, Zedeler K, Holck S, Schiødt T, Mouridsen HT. Medullary carcinoma of the breast. Prevalence and prognostic importance of classical risk factors in breast cancer. Eur J Cancer. 1995;31A(13–14):2289–95.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Wang XX, Jiang YZ, Liu XY, Li JJ, Song CG, Shao ZM. Difference in characteristics and outcomes between medullary breast carcinoma and invasive ductal carcinoma: a population based study from SEER 18 database. Oncotarget. 2016;7(16):22665–73.PubMedPubMedCentralGoogle Scholar
  72. 72.
    Yilmaz E, Lebe B, Balci P, Sal S, Canda T. Comparison of mammographic and sonographic findings in typical and atypical medullary carcinomas of the breast. Clin Radiol. 2002;57(7):640–5.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Jeong SJ, Lim HS, Lee JS, Park MH, Yoon JH, Park JG, et al. Medullary carcinoma of the breast: MRI findings. AJR Am J Roentgenol. 2012;198(5):W482–7.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Ridolfi RL, Rosen PP, Port A, Kinne D, Mike V. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer. 1977;40(4):1365–85.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Racz MM, Pommier RF, Troxell ML. Fine-needle aspiration cytology of medullary breast carcinoma: report of two cases and review of the literature with emphasis on differential diagnosis. Diagn Cytopathol. 2007;35(6):313–8.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Xu R, Feiner H, Li P, Yee H, Inghirami G, Delgado Y, et al. Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast. Arch Pathol Lab Med. 2003;127(11):1458–64.Google Scholar
  77. 77.
    Rodriguez-Pinilla SM, Rodríguez-Gil Y, Moreno-Bueno G, Sarrió D, Martin-Guijarro Mdel C, Hernandez L, et al. Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study. Am J Surg Pathol 2007;31(4):501–8.Google Scholar
  78. 78.
    Huober J, Gelber S, Goldhirsch A, Coates AS, Viale G, Öhlschlegel C, et al. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Ann Oncol. 2012;23(11):2843–51.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Mateo AM, Pezzi TA, Sundermeyer M, Kelley CA, Klimberg VS, Pezzi CM. Atypical medullary carcinoma of the breast has similar prognostic factors and survival to typical medullary breast carcinoma: 3,976 cases from the National Cancer Data Base. J Surg Oncol. 2016;114(5):533–6.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Rakha EA, Aleskandarany M, El-Sayed ME, Blamey RW, Elston CW, Ellis IO, et al. The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer. 2009;45(10):1780–7.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860–7.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    O'Malley FP, Bane A. An update on apocrine lesions of the breast. Histopathology. 2008;52(1):3–10.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Tanaka K, Imoto S, Wada N, Sakemura N, Hasebe K. Invasive apocrine carcinoma of the breast: clinicopathologic features of 57 patients. Breast J. 2008;14(2):164–8.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Vranic S, Schmitt F, Sapino A, Costa JL, Reddy S, Castro M, et al. Apocrine carcinoma of the breast: a comprehensive review. Histol Histopathol. 2013;28(11):1393–409.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Zhang N, Zhang H, Chen T, Yang Q. Dose invasive apocrine adenocarcinoma has worse prognosis than invasive ductal carcinoma of breast: evidence from SEER database. Oncotarget. 2017;8(15):24579–92.PubMedPubMedCentralGoogle Scholar
  86. 86.
    Gilles R, Lesnik A, Guinebretière JM, Tardivon A, Masselot J, Contesso G, et al. Apocrine carcinoma: clinical and mammographic features. Radiology. 1994;190(2):495–7.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Yuen S, Uematsu T, Kasami M, Tanaka K, Kimura K, Sanuki J, et al. Breast carcinomas with strong high-signal intensity on T2-weighted MR images: pathological characteristics and differential diagnosis. J Magn Reson Imaging. 2007;25(3):502–10.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Seo KJ, An YY, Whang IY, Chang ED, Kang BJ, Kim SH, et al. Sonography of invasive apocrine carcinoma of the breast in five cases. Korean J Radiol. 2015;16(5):1006–11.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Vranic S, Gatalica Z, Deng H, Frkovic-Grazio S, Lee LM, Gurjeva O, et al. ER-alpha36, a novel isoform of ER-alpha66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast. J Clin Pathol. 2011;64(1):54–7.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Vranic S, Marchiò C, Castellano I, Botta C, Scalzo MS, Bender RP, et al. Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast. Hum Pathol. 2015;46(9):1350–9.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Dellapasqua S, Maisonneuve P, Viale G, Pruneri G, Mazzarol G, Ghisini R, et al. Immunohistochemically defined subtypes and outcome of apocrine breast cancer. Clin Breast Cancer. 2013;13(2):95–102.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Turner NC, Reis-Filho JS. Tackling the diversity of triple-negative breast cancer. Clin Cancer Res. 2013;19(23):6380–8.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Weisman PS, Ng CK, Brogi E, Eisenberg RE, Won HH, Piscuoglio S, et al. Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. Mod Pathol. 2016;29(5):476–88.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res. 2014;16(4):406.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Agarwal C, Pujani M, Sharma N, Rana D, Prajapati D. Apocrine carcinoma of breast: a rare entity posing cytological challenge. Diagn Cytopathol. 2017;45(12):1156–8.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Ng WK. Fine needle aspiration cytology of apocrine carcinoma of the breast. Review of cases in a three-year period. Acta Cytol. 2002;46(3):507–12.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Abati AD, Kimmel M, Rosen PP. Apocrine mammary carcinoma. A clinicopathologic study of 72 cases. Am J Clin Pathol. 1990;94(4):371–7.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Weigelt B, Eberle C, Cowell CF, Ng CK, Reis-Filho JS. Metaplastic breast carcinoma: more than a special type. Nat Rev Cancer. 2014;14(3):147–8.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Downs-Kelly E, Nayeemuddin KM, Albarracin C, Wu Y, Hunt KK, Gilcrease MZ. Matrix-producing carcinoma of the breast: an aggressive subtype of metaplastic carcinoma. Am J Surg Pathol. 2009;33(4):534–41.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Yamaguchi R, Horii R, Maeda I, Suga S, Makita M, Iwase T, et al. Clinicopathologic study of 53 metaplastic breast carcinomas: their elements and prognostic implications. Hum Pathol. 2010;41(5):679–85.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol. 2007;14(1):166–73.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Nelson RA, Guye ML, Luu T, Lai LL. Survival outcomes of metaplastic breast cancer patients: results from a US population-based analysis. Ann Surg Oncol. 2015;22(1):24–31.PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Langlands F, Cornford E, Rakha E, Dall B, Gutteridge E, Dodwell D, et al. Imaging overview of metaplastic carcinomas of the breast: a large study of 71 cases. Br J Radiol. 2016:20140644.Google Scholar
  104. 104.
    Lang R, Fan Y, Fu X, Fu L. Metaplastic breast carcinoma with extensive osseous differentiation: a report of two cases and review of the literature. Tumori. 2011;97(4):e1–5.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Leddy R, Irshad A, Rumboldt T, Cluver A, Campbell A, Ackerman S. Review of metaplastic carcinoma of the breast: imaging findings and pathologic features. J Clin Imaging Sci. 2012;2:21.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    McKinnon E, Xiao P. Metaplastic carcinoma of the breast. Arch Pathol Lab Med. 2015;139(6):819–22.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Yang WT, Hennessy B, Broglio K, Mills C, Sneige N, Davis WG, et al. Imaging differences in metaplastic and invasive ductal carcinomas of the breast. AJR Am J Roentgenol. 2007;189(6):1288–93.PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Nayak A, Wu Y, Gilcrease MZ. Primary squamous cell carcinoma of the breast: predictors of locoregional recurrence and overall survival. Am J Surg Pathol. 2013;37(6):867–73.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    DeLair DF, Corben AD, Catalano JP, Vallejo CE, Brogi E, Tan LK. Non-mammary metastases to the breast and axilla: a study of 85 cases. Mod Pathol. 2013;26(3):343–9.PubMedCrossRefPubMedCentralGoogle Scholar
  110. 110.
    Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. Hum Pathol. 1989;20(7):628–35.PubMedCrossRefPubMedCentralGoogle Scholar
  111. 111.
    Gobbi H, Simpson JF, Jensen RA, Olson SJ, Page DL. Metaplastic spindle cell breast tumors arising within papillomas, complex sclerosing lesions, and nipple adenomas. Mod Pathol. 2003;16(9):893–901.PubMedCrossRefPubMedCentralGoogle Scholar
  112. 112.
    Carter MR, Hornick JL, Lester S, Fletcher CD. Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. Am J Surg Pathol. 2006;30(3):300–9.PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Dwyer JB, Clark BZ. Low-grade fibromatosis-like spindle cell carcinoma of the breast. Arch Pathol Lab Med. 2015;139(4):552–7.PubMedCrossRefPubMedCentralGoogle Scholar
  114. 114.
    Kawaguchi K, Shin SJ. Immunohistochemical staining characteristics of low-grade adenosquamous carcinoma of the breast. Am J Surg Pathol. 2012;36(7):1009–20.PubMedCrossRefPubMedCentralGoogle Scholar
  115. 115.
    Geyer FC, Lambros MB, Natrajan R, Mehta R, Mackay A, Savage K, et al. Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast. Mod Pathol. 2010;23(7):951–60.PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    Lui PC, Tse GM, Tan PH, Jayaram G, Putti TC, Chaiwun B, et al. Fine-needle aspiration cytology of metaplastic carcinoma of the breast. J Clin Pathol. 2007;60(5):529–33.PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Murata T, Ihara S, Kato H, Tanigawa K, Higashiguchi T, Imai T, et al. Matrix-producing carcinoma of the breast: case report with radiographical and cytopathological features. Pathol Int. 1998;48(10):824–8.PubMedCrossRefPubMedCentralGoogle Scholar
  118. 118.
    Joshi D, Singh P, Zonunfawni Y, Gangane N. Metaplastic carcinoma of the breast: cytological diagnosis and diagnostic pitfalls. Acta Cytol. 2011;55(4):313–8.PubMedCrossRefPubMedCentralGoogle Scholar
  119. 119.
    Rakha EA, Tan PH, Varga Z, Tse GM, Shaaban AM, Climent F, et al. Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. Br J Cancer. 2015;112(2):283–9.PubMedCrossRefPubMedCentralGoogle Scholar
  120. 120.
    Rakha EA, Coimbra ND, Hodi Z, Juneinah E, Ellis IO, Lee AH. Immunoprofile of metaplastic carcinomas of the breast. Histopathology. 2017;70(6):975–85.PubMedCrossRefPubMedCentralGoogle Scholar
  121. 121.
    Davis WG, Hennessy B, Babiera G, Hunt K, Valero V, Buchholz TA, et al. Metaplastic sarcomatoid carcinoma of the breast with absent or minimal overt invasive carcinomatous component: a misnomer. Am J Surg Pathol. 2005;29(11):1456–63.PubMedCrossRefPubMedCentralGoogle Scholar
  122. 122.
    Lester TR, Hunt KK, Nayeemuddin KM, Bassett RL Jr, Gonzalez-Angulo AM, Feig BW, et al. Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers. Breast Cancer Res Treat 2012;131(1):41–48.Google Scholar
  123. 123.
    Lacroix-Triki M, Geyer FC, Lambros MB, Savage K, Ellis IO, Lee AH, et al. Beta-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast. Mod Pathol. 2010;23(11):1438–48.PubMedCrossRefPubMedCentralGoogle Scholar
  124. 124.
    Ng CKY, Piscuoglio S, Geyer FC, Burke KA, Pareja F, Eberle CA, et al. The landscape of somatic genetic alterations in metaplastic breast carcinomas. Clin Cancer Res. 2017;23(14):3859–70.PubMedPubMedCentralCrossRefGoogle Scholar
  125. 125.
    Cimino-Mathews A, Sharma R, Illei PB, Vang R, Argani P. A subset of malignant phyllodes tumors express p63 and p40: a diagnostic pitfall in breast core needle biopsies. Am J Surg Pathol. 2014;38(12):1689–96.PubMedPubMedCentralCrossRefGoogle Scholar
  126. 126.
    Rungta S, Kleer CG. Metaplastic carcinomas of the breast: diagnostic challenges and new translational insights. Arch Pathol Lab Med. 2012;136(8):896–900.PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Boecker W, Stenman G, Loening T, Andersson MK, Sinn HP, Barth P, et al. Differentiation and histogenesis of syringomatous tumour of the nipple and low-grade adenosquamous carcinoma: evidence for a common origin. Histopathology. 2014;65(1):9–23.PubMedCrossRefPubMedCentralGoogle Scholar
  128. 128.
    Cimino-Mathews A, Verma S, Figueroa-Magalhaes MC, Jeter SC, Zhang Z, Argani P, et al. A clinicopathologic analysis of 45 patients with metaplastic breast carcinoma. Am J Clin Pathol. 2016;145(3):365–72.PubMedCrossRefPubMedCentralGoogle Scholar
  129. 129.
    Hennessy BT, Giordano S, Broglio K, Duan Z, Trent J, Buchholz TA, et al. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol. 2006;17(4):605–13.PubMedCrossRefPubMedCentralGoogle Scholar
  130. 130.
    Jung SY, Kim HY, Nam BH, Min SY, Lee SJ, Park C, et al. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat. 2010;120(3):627–37.PubMedCrossRefPubMedCentralGoogle Scholar
  131. 131.
    Nagao T, Kinoshita T, Hojo T, Tsuda H, Tamura K, Fujiwara Y. The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics. Breast. 2012;21(3):289–95.PubMedCrossRefPubMedCentralGoogle Scholar
  132. 132.
    El Zein D, Hughes M, Kumar S, Peng X, Oyasiji T, Jabbour H, et al. Metaplastic carcinoma of the breast is more aggressive than triple-negative breast cancer: a study from a single institution and review of literature. Clin Breast Cancer. 2017;17(5):382–91.PubMedPubMedCentralCrossRefGoogle Scholar
  133. 133.
    Zhang Y, Lv F, Yang Y, Qian X, Lang R, Fan Y, et al. Clinicopathological features and prognosis of metaplastic breast carcinoma: experience of a major Chinese cancer center. PLoS One. 2015;10(6):e0131409.PubMedPubMedCentralCrossRefGoogle Scholar
  134. 134.
    Lai HW, Tseng LM, Chang TW, Kuo YL, Hsieh CM, Chen ST, et al. The prognostic significance of metaplastic carcinoma of the breast (MCB)—a case controlled comparison study with infiltrating ductal carcinoma. Breast. 2013;22(5):968–73.PubMedCrossRefPubMedCentralGoogle Scholar
  135. 135.
    Tan QT, Chuwa EW, Chew SH, Lim-Tan SK, Lim SH. Low-grade adenosquamous carcinoma of the breast: a diagnostic and clinical challenge. Int J Surg. 2015;19:22–6.PubMedCrossRefPubMedCentralGoogle Scholar
  136. 136.
    Gobbi H, Simpson JF, Borowsky A, Jensen RA, Page DL. Metaplastic breast tumors with a dominant fibromatosis-like phenotype have a high risk of local recurrence. Cancer. 1999;85(10):2170–82.PubMedCrossRefPubMedCentralGoogle Scholar
  137. 137.
    Jaso J, Malhotra R. Adenoid cystic carcinoma. Arch Pathol Lab Med. 2011;135(4):511–5.PubMedPubMedCentralGoogle Scholar
  138. 138.
    Treitl D, Radkani P, Rizer M, El Hussein S, Paramo JC, Mesko TW. Adenoid cystic carcinoma of the breast, 20 years of experience in a single center with review of literature. Breast Cancer. 2017.  https://doi.org/10.1007/s12282-017-0780-1.
  139. 139.
    Boujelbene N, Khabir A, Boujelbene N, Jeanneret Sozzi W, Mirimanoff RO, Khanfir K. Clinical review—breast adenoid cystic carcinoma. Breast. 2012;21(2):124–7.PubMedCrossRefPubMedCentralGoogle Scholar
  140. 140.
    Glazebrook KN, Reynolds C, Smith RL, Gimenez EI, Boughey JC. Adenoid cystic carcinoma of the breast. AJR Am J Roentgenol. 2010;194(5):1391–6.PubMedCrossRefPubMedCentralGoogle Scholar
  141. 141.
    Foschini MP, Morandi L, Asioli S, Giove G, Corradini AG, Eusebi V. The morphological spectrum of salivary gland type tumours of the breast. Pathology. 2017;49(2):215–27.PubMedCrossRefPubMedCentralGoogle Scholar
  142. 142.
    Marchiò C, Weigelt B, Reis-Filho JS. Adenoid cystic carcinomas of the breast and salivary glands (or ‘The strange case of Dr Jekyll and Mr Hyde’ of exocrine gland carcinomas). J Clin Pathol. 2010;63(3):220–8.PubMedCrossRefPubMedCentralGoogle Scholar
  143. 143.
    Shin SJ, Rosen PP. Solid variant of mammary adenoid cystic carcinoma with basaloid features: a study of nine cases. Am J Surg Pathol. 2002;26(4):413–20.PubMedCrossRefPubMedCentralGoogle Scholar
  144. 144.
    Mastropasqua MG, Maiorano E, Pruneri G, Orvieto E, Mazzarol G, Vento AR, et al. Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. Mod Pathol. 2005;18(10):1277–82.PubMedCrossRefPubMedCentralGoogle Scholar
  145. 145.
    Azoulay S, Laé M, Fréneaux P, Merle S, Al Ghuzlan A, Chnecker C, et al. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol. 2005;18(12):1623–31.PubMedCrossRefPubMedCentralGoogle Scholar
  146. 146.
    Nakai T, Ichihara S, Kada A, Ito N, Moritani S, Kawasaki T, et al. The unique luminal staining pattern of cytokeratin 5/6 in adenoid cystic carcinoma of the breast may aid in differentiating it from its mimickers. Virchows Arch. 2016;469(2):213–22.PubMedCrossRefPubMedCentralGoogle Scholar
  147. 147.
    Wetterskog D, Lopez-Garcia MA, Lambros MB, A'Hern R, Geyer FC, Milanezi F, et al. Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol. 2012;226(1):84–96.PubMedCrossRefPubMedCentralGoogle Scholar
  148. 148.
    Persson M, Andrén Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A. 2009;106(44):18740–4.PubMedPubMedCentralCrossRefGoogle Scholar
  149. 149.
    Poling JS, Yonescu R, Subhawong AP, Sharma R, Argani P, Ning Y, et al. MYB labeling by immunohistochemistry is more sensitive and specific for breast adenoid cystic carcinoma than MYB labeling by FISH. Am J Surg Pathol. 2017;41(7):973–9.PubMedCrossRefPubMedCentralGoogle Scholar
  150. 150.
    Kim J, Geyer FC, Martelotto LG, Ng CKY, Lim RS, Selenica P, et al. MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene. J Pathol. 2017.  https://doi.org/10.1002/path.5006.
  151. 151.
    Saqi A, Mercado CL, Hamele-Bena D. Adenoid cystic carcinoma of the breast diagnosed by fine-needle aspiration. Diagn Cytopathol. 2004;30(4):271–4.PubMedCrossRefPubMedCentralGoogle Scholar
  152. 152.
    Ilkay TM, Gozde K, Ozgur S, Dilaver D. Diagnosis of adenoid cystic carcinoma of the breast using fine-needle aspiration cytology: a case report and review of the literature. Diagn Cytopathol. 2015;43(9):722–6.PubMedCrossRefPubMedCentralGoogle Scholar
  153. 153.
    Rabban JT, Swain RS, Zaloudek CJ, Chase DR, Chen YY. Immunophenotypic overlap between adenoid cystic carcinoma and collagenous spherulosis of the breast: potential diagnostic pitfalls using myoepithelial markers. Mod Pathol. 2006;19(10):1351–7.PubMedCrossRefGoogle Scholar
  154. 154.
    Welsh JL, Keeney MG, Hoskin TL, Glazebrook KN, Boughey JC, Shah SS, et al. Is axillary surgery beneficial for patients with adenoid cystic carcinoma of the breast? J Surg Oncol. 2017;116(6):690–5.PubMedCrossRefGoogle Scholar
  155. 155.
    Ghabach B, Anderson WF, Curtis RE, Huycke MM, Lavigne JA, Dores GM. Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study. Breast Cancer Res. 2010;12(4):R54.PubMedPubMedCentralCrossRefGoogle Scholar
  156. 156.
    Fusco N, Geyer FC, De Filippo MR, Martelotto LG, Ng CK, Piscuoglio S, et al. Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer. Mod Pathol. 2016;29(11):1292–305.PubMedPubMedCentralCrossRefGoogle Scholar
  157. 157.
    McDivitt RW, Stewart FW. Breast carcinoma in children. JAMA. 1966;195(5):388–90.PubMedCrossRefPubMedCentralGoogle Scholar
  158. 158.
    Horowitz DP, Sharma CS, Connolly E, Gidea-Addeo D, Deutsch I. Secretory carcinoma of the breast: results from the survival, epidemiology and end results database. Breast. 2012;21(3):350–3.PubMedCrossRefPubMedCentralGoogle Scholar
  159. 159.
    Mun SH, Ko EY, Han BK, Shin JH, Kim SJ, Cho EY. Secretory carcinoma of the breast: sonographic features. J Ultrasound Med. 2008;27(6):947–54.PubMedCrossRefPubMedCentralGoogle Scholar
  160. 160.
    Paeng MH, Choi HY, Sung SH, Moon BI, Shim SS. Secretory carcinoma of the breast. J Clin Ultrasound. 2003;31(8):425–9.PubMedCrossRefPubMedCentralGoogle Scholar
  161. 161.
    Del Castillo M, Chibon F, Arnould L, Croce S, Ribeiro A, Perot G, et al. Secretory breast carcinoma: a histopathologic and genomic spectrum characterized by a joint specific ETV6-NTRK3 gene fusion. Am J Surg Pathol. 2015;39(11):1458–67.PubMedCrossRefPubMedCentralGoogle Scholar
  162. 162.
    Li D, Xiao X, Yang W, Shui R, Tu X, Lu H, et al. Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature. Mod Pathol. 2012;25(4):567–75.PubMedCrossRefPubMedCentralGoogle Scholar
  163. 163.
    Lamovec J, Bracko M. Secretory carcinoma of the breast: light microscopical, immunohistochemical and flow cytometric study. Mod Pathol. 1994;7(4):475–9.PubMedPubMedCentralGoogle Scholar
  164. 164.
    Lae M, Fréneaux P, Sastre-Garau X, Chouchane O, Sigal-Zafrani B, Vincent-Salomon A. Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum. Mod Pathol. 2009;22(2):291–8.PubMedCrossRefPubMedCentralGoogle Scholar
  165. 165.
    Krings G, Joseph NM, Bean GR, Solomon D, Onodera C, Talevich E, et al. Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas. Mod Pathol. 2017;30(8):1086–99.PubMedCrossRefPubMedCentralGoogle Scholar
  166. 166.
    Shanthi V, Rama Krishna BA, Rao NM, Sujatha C. Cytodiagnosis of secretory carcinoma of the breast. J Cytol. 2012;29(1):63–5.PubMedPubMedCentralCrossRefGoogle Scholar
  167. 167.
    Jayaram G, Looi LM, Yip CH. Fine needle aspiration cytology of secretory carcinoma of breast: a case report. Malays J Pathol. 1997;19(1):69–73.PubMedPubMedCentralGoogle Scholar
  168. 168.
    Osako T, Takeuchi K, Horii R, Iwase T, Akiyama F. Secretory carcinoma of the breast and its histopathological mimics: value of markers for differential diagnosis. Histopathology. 2013;63(4):509–19.PubMedPubMedCentralGoogle Scholar
  169. 169.
    D'Alfonso TM, Ginter PS, Liu YF, Shin SJ. Cystic hypersecretory (in situ) carcinoma of the breast: a clinicopathologic and immunohistochemical characterization of 10 cases with clinical follow-up. Am J Surg Pathol. 2014;38(1):45–53.PubMedCrossRefPubMedCentralGoogle Scholar
  170. 170.
    Peintinger F, Leibl S, Reitsamer R, Moinfar F. Primary acinic cell carcinoma of the breast: a case report with long-term follow-up and review of the literature. Histopathology. 2004;45(6):645–8.PubMedCrossRefPubMedCentralGoogle Scholar
  171. 171.
    Geyer FC, Pareja F, Weigelt B, Rakha E, Ellis IO, Schnitt SJ, et al. The spectrum of triple-negative breast disease: high- and low-grade lesions. Am J Pathol. 2017;187(10):2139–51.PubMedCrossRefGoogle Scholar
  172. 172.
    Eusebi V, Damiani S, Ellis IO, Azzopardi JG, Rosai J. Breast tumor resembling the tall cell variant of papillary thyroid carcinoma: report of 5 cases. Am J Surg Pathol. 2003;27(8):1114–8.PubMedCrossRefPubMedCentralGoogle Scholar
  173. 173.
    Cameselle-Teijeiro J, Abdulkader I, Barreiro-Morandeira F, Ruiz-Ponte C, Reyes-Santias R, Chavez E, et al. Breast tumor resembling the tall cell variant of papillary thyroid carcinoma: a case report. Int J Surg Pathol. 2006;14(1):79–84.PubMedCrossRefGoogle Scholar
  174. 174.
    Masood S, Davis C, Kubik MJ. Changing the term “breast tumor resembling the tall cell variant of papillary thyroid carcinoma” to “tall cell variant of papillary breast carcinoma”. Adv Anat Pathol. 2012;19(2):108–10.PubMedCrossRefGoogle Scholar
  175. 175.
    Chiang S, Weigelt B, Wen HC, Pareja F, Raghavendra A, Martelotto LG, et al. IDH2 mutations define a unique subtype of breast cancer with altered nuclear polarity. Cancer Res. 2016;76(24):7118–29.PubMedPubMedCentralCrossRefGoogle Scholar
  176. 176.
    Bhargava R, Florea AV, Pelmus M, Jones MW, Bonaventura M, Wald A, et al. Breast tumor resembling tall cell variant of papillary thyroid carcinoma: a solid papillary neoplasm with characteristic immunohistochemical profile and few recurrent mutations. Am J Clin Pathol. 2017;147(4):399–410.PubMedCrossRefPubMedCentralGoogle Scholar
  177. 177.
    Foschini MP, Asioli S, Foreid S, Cserni G, Ellis IO, Eusebi V, et al. Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms: a unique invasive tumor with indolent behavior. Am J Surg Pathol. 2017;41(7):887–95.PubMedCrossRefPubMedCentralGoogle Scholar
  178. 178.
    Tosi AL, Ragazzi M, Asioli S, Del Vecchio M, Cavalieri M, Eusebi LH, et al. Breast tumor resembling the tall cell variant of papillary thyroid carcinoma: report of 4 cases with evidence of malignant potential. Int J Surg Pathol. 2007;15(1):14–9.PubMedCrossRefPubMedCentralGoogle Scholar
  179. 179.
    Hameed O, Perry A, Banerjee R, Zhu X, Pfeifer JD. Papillary carcinoma of the breast lacks evidence of RET rearrangements despite morphological similarities to papillary thyroid carcinoma. Mod Pathol. 2009;22(9):1236–42.PubMedCrossRefPubMedCentralGoogle Scholar
  180. 180.
    Colella R, Guerriero A, Giansanti M, Sidoni A, Bellezza G. An additional case of breast tumor resembling the tall cell variant of papillary thyroid carcinoma. Int J Surg Pathol. 2015;23(3):217–20.PubMedCrossRefPubMedCentralGoogle Scholar
  181. 181.
    Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, et al. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin. 2010;60(6):351–75.PubMedCrossRefPubMedCentralGoogle Scholar
  182. 182.
    Cristofanilli M, Valero V, Buzdar AV, Kau SW, Broglio KR, Gonzalez-Angulo AM, et al. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer. 2007;110(7):1436–44.PubMedCrossRefPubMedCentralGoogle Scholar
  183. 183.
    Raghav K, French JT, Ueno NT, Lei X, Krishnamurthy S, Reuben JM, et al. Inflammatory Breast Cancer: a distinct clinicopathologic entity transcending histological distinction. PLoS One. 2016;11(1):e0145534.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Javier A. Arias-StellaIII
    • 1
  • Isabel Alvarado-Cabrero
    • 2
  • Fresia Pareja
    • 1
  1. 1.Department of PathologyMemorial Sloan Kettering Cancer CenterNew YorkUSA
  2. 2.Department of Pathology, Hospital de Oncologia, Centro Medico Nacional Siglo XXIInstituto Mexicano del Seguro SocialMexico CityMexico

Personalised recommendations